menatetrenone and Dementia

menatetrenone has been researched along with Dementia* in 1 studies

Reviews

1 review(s) available for menatetrenone and Dementia

ArticleYear
[Dementia and fracture].
    Clinical calcium, 2010, Volume: 20, Issue:9

    A high incidence of fractures, particularly of the hip, represents an important problem in patients with AD, who are prone to falls and may have osteoporosis. The odds ratio reported for fracture prevalence between elderly persons with and without AD is 6.9. We previously demonstrated that deficiency of 25-hydroxyvitamin D due to sunlight deprivation and vitamin K deficiency due to malnutrition contributed to reduced bone mineral density in patients with AD and were associated with a high risk of hip fracture. Treatment with menatetrenone, risedronate or regular sunlight exposure are safe and effective in increasing bone mass and reducing the risk of hip fracture in patients with AD.

    Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism, Secondary; Osteoporosis; Risedronic Acid; Risk; Risk Factors; Sunlight; Vitamin D Deficiency; Vitamin K 2; Vitamin K Deficiency

2010